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Abstract
 
B cells undergo a complex series of maturation and selection steps in the bone marrow and
spleen during differentiation into mature immune effector cells. The tumor necrosis factor
(TNF) family member B cell activating factor of the TNF family (BAFF) (BLyS/TALL-1) plays
an important role in B cell homeostasis. BAFF and its close homologue a proliferation-inducing
ligand (APRIL) have both been shown to interact with at least two receptors, B cell maturation
antigen (BCMA) and transmembrane activator and cyclophilin ligand interactor (TACI), how-
ever their relative contribution in transducing BAFF signals in vivo remains unclear. To func-
tionally inactivate both BAFF and APRIL, mice transgenic for a soluble form of TACI were
generated. They display a developmental block of B cell maturation in the periphery, leading to
a severe depletion of marginal zone and follicular B2 B cells, but not of peritoneal B1 B cells. In
contrast, mice transgenic for a soluble form of BCMA, which binds APRIL, have no detectable
B cell phenotype. This demonstrates a crucial role for BAFF in B cell maturation and strongly
suggests that it signals via a BCMA-independent pathway and in an APRIL-dispensable way.
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Introduction
 
In adult mice, B cell precursors in the bone marrow rear-
range their Ig genes to yield immature B cells, which subse-
quently undergo negative selection steps before differentia-
tion into mature B cells through at least two successive
transitional stages (T1 and T2). Newly formed B cells leav-
ing the bone marrow have a short half-life and remain
largely confined to blood circulation and defined areas of the
spleen, as they lack adhesion molecules necessary for ex-
travasation in peripheral lymphoid organs such as lymph
nodes. Only a fraction of these newly formed B cells eventu-
ally enters the pool of long-lived, recirculating follicular B
cells populating lymphoid organs, which are referred to as
B2 B cells. Upon antigen encounter and T cell help, follicu-
lar B cells undergo expansion, affinity maturation, isotype
switching, and differentiation into memory cells or anti-
body-secreting plasma cells (1–3). In contrast, B1 B cells rep-
resent a self-renewing population of the peritoneal and pleu-
ral cavities, which mainly produce natural antibodies against
bacterial antigens in a T cell–independent manner. These
cells are believed to give rise to IgA-secreting plasmocytes in
the intestine and to play an important role in the innate im-
mune response (1, 4, 5). Moreover, distinct extrafollicular
naive and memory B2 B cell populations reside in the mar-
ginal zone of the spleen at the boundary between red and
white pulp and participate in early T cell–independent anti-
body responses against blood-borne particulate antigens (6).
The signals promoting survival and differentiation of
newly formed B cells are not well understood. A B cell ac-
tivating factor of the TNF family (BAFF) (BLyS, TALL-1,
zTNF4), is a ligand that is clearly involved in the regulation
of B cell homeostasis, as BAFF transgenic mice display se-
vere B cell hyperplasia, hyperglobulinemia, and autoim-
mune manifestations (7–9). BAFF has been demonstrated
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to interact with two receptors, B cell maturation antigen
(BCMA) and transmembrane activator and cyclophilin
ligand interactor (TACI), both of which also bind to a sec-
ond ligand, a proliferation-inducing ligand (APRIL; refer-
ences 7, 10, and 11). To gain insight into the role of in-
dividual proteins within this complex system, targeted
inactivation of selected receptors or ligands is a valuable ap-
proach. BCMA-deficient mice have been recently reported
to be normal (12), whereas TACI-deficient mice display
moderate B cell hyperplasia with a partial defect in T cell–
independent humoral responses, but are otherwise largely
normal (13, 14). In this study, we have generated BAFF-
and APRIL-deficient mice by overexpressing soluble forms
of their receptors. We describe a severe B lymphopenia in
mice lacking functional BAFF, which results from a block-
ade of B cell maturation in the periphery.
 
Materials and Methods
 
Transgenic Mice.
 
A transgenic vector containing human 
 
 
 
1
antitrypsin promoter (nucleotides –6,602 to –5,328 as HindIII/
XbaI fragment) and the 3
 
 
 
 end of rabbit 
 
 
 
-globin gene (nucle-
otides 421–1,592 as XbaI/XhoI fragment, comprising the end of
exon 2, intron 2, exon 3, and the poly A addition signal) was
provided by K. Araki and M. Araki, Kumamoto University, Ku-
mamoto, Japan (15). A cassette encoding the signal peptide of hu-
man Ig G heavy chain, the extracellular domain of human TACI
(amino acids 2–118) or murine BCMA (amino acids 1–46) and
the Fc domain of human Ig G1 was inserted in the transgenic
vector using the EcoRI site of 
 
 
 
-globin exon 3. Transgenic mice
were generated by microinjection of the HindIII/XhoI excised
construct into fertilized (C57BL/6 
 
  
 
DBA/2) F2 oocytes, and
screened by PCR using oligonucleotides 5
 
 
 
CAGACCCA-
CATAAAGAGCCTAC3
 
 
 
 and 5
 
 
 
CCGATGGAAAAATGG-
AGC3
 
 
 
. Expression of the transgene was determined by Western
blot analysis of 0.5 
 
 
 
l of serum using horseradish peroxidase-cou-
pled goat anti–human IgG.
 
ELISA Assays.
 
Receptor-ligand ELISA. ELISA plates were
coated overnight with mouse anti–human IgG (5 
 
 
 
g/ml in 50 mM
carbonate buffer, pH 9.6; Jackson ImmunoResearch Laboratories).
After blocking, the following additions were performed, all for 1 h
at 37
 
 
 
C and separated by washing steps: (i) saturating concentra-
tions of receptor:Fc (100- and 25-fold diluted serum for transgenic
muBCMA:Fc and hTACI:Fc, respectively, corresponding to 250
ng/ml of recombinant receptors); (ii) indicated concentrations of
Flag-tagged murine BAFF, APRIL, or TNF; (iii) biotinylated anti-
Flag M2 antibody (250 ng/ml; Sigma-Aldrich); and (iv) horserad-
ish peroxidase–coupled streptavidin (1/4,000). Cloning and ex-
pression of Flag-tagged ligands has been described previously (16).
 
Antibody Quantification.
 
Quantification of Ig isotypes in
mouse sera was performed by ELISA. Briefly, plates were coated
with goat anti–mouse IgG plus IgM (2 
 
 
 
g/ml; Caltag) and serial
dilutions of sera or of purified mouse IgG1, 2a, 2b, 3, M, and A
standards were added. Captured antibodies were revealed with bi-
otinylated anti-IgG1, 2a, 2b, 3, M, and A (1/2,000; Caltag), re-
spectively, followed by horseradish peroxidase–coupled streptavi-
din (1/4,000). Concentrations were inferred from the IC
 
50
 
 values.
 
FACS
 
® 
 
Analysis.
 
The following antibodies were purchased
from BD PharMingen: anti-CD3
 
 
 
–FITC (17A2); anti-CD4-Cy-
Chrome (RM4–5); anti-CD5–PE (53–7.3); anti-CD16/CD32
(2.4G2, Fc Block™); anti-CD21 (7G6); anti-CD23–FITC
 
(B3B4); anti-CD43–FITC (S7); anti-B220–PE; anti-B220–Cy-
Chrome (RA3–6B2); anti–IgMa plus b-PE (R6–60.2); anti-
BP1–PE (6C3); anti-TCR-
 
  
 
–FITC (H57–597); and anti-
TCR-
 
  
 
-PE (GL3). Anti-IgD–PE (11–26) was from Southern
Biotechnology Associates and anti-CD62L–PE (MEL-14) was
from Caltag. Anti-CD8–Cy5 (53–6.7), anti-CD24–APC (M1/
69), and biotinylated anti-CD21 (7G6) were purified from hy-
bridoma culture supernatant and conjugated in our laboratory ac-
cording to standard procedures. Cells were treated with anti-
CD16/CD32 (2.4G2, as culture supernatant) before staining, and
analyzed using a four color FACSCalibur™ and CELLQuest™
program (Becton Dickinson).
 
Immunohistochemistry.
 
Antibodies for immunohistology in-
cluded anti-CD3
 
 
 
–biotin (145–2C11), anti-CD11b (M1/70),
anti-CD11c-biotin (HL3), anti-CD35 (8C12), anti-B220 (RA3–
6B2) (all from BD PharMingen), and anti-B220–biotin (RA3–
6B2; Caltag). Acetone-fixed 7-
 
 
 
m frozen sections were stained
with horseradish peroxidase and alkaline phosphatase substrates
according to standard procedures (17).
 
NH
 
2
 
-Terminal Sequence Determination.
 
TACI:Fc (amino acids
2–148) and TACI:Fc (amino acids 2–118) were expressed in 293
cells and purified with protein A-Sepharose. Purified proteins (10
 
 
 
g) were reduced, blotted onto polyvinylidene difluoride mem-
branes, and stained with Ponceau S. Bands of interest were sub-
mitted to automated Edman degradation using an ABI 120A gas
phase sequencer coupled to an ABI 120A analyzer equipped with
a PTH C18 2.1 
 
 
 
 250 mm column. Data was analyzed using
ABI 610 software.
 
Results and Discussion
 
To investigate the role of BAFF and/or APRIL in vivo,
we generated mice transgenic for soluble, secreted forms of
either BCMA or TACI under the control of a liver pro-
moter, with the expectation that both circulating transgenic
proteins would act as BAFF and APRIL inhibitors and gen-
erate a similar phenotype. To this purpose, we used the en-
tire extracellular domain of murine BCMA (amino acids
1–46) and the NH
 
2
 
-terminal portion of human TACI
(amino acids 2–118), fused to the Fc portion of human IgG1
(Fig. 1 A and B). Although the extracellular domain of
TACI comprises 144 amino acids, initial transfection exper-
iments revealed a major proteolytic cleavage site at Arg
 
122
 
(sequence RRQR-SG), prompting us to use a shorter ver-
sion. Despite this precaution, the transgenic TACI:Fc pro-
tein recovered at concentrations of 4 and 6 
 
 
 
g/ml in sera of two
transgenic lines was extensively processed (Fig. 1 C), proba-
bly at Lys
 
108
 
 (CENK-LR) and Arg
 
110
 
 (NKLR-SP), as inferred
from Edman sequencing of the processed recombinant pro-
tein. In contrast, BCMA:Fc, which was expressed at higher
concentrations in two lines of transgenic mice (25 and 100
 
 
 
g/ml, respectively), remained largely intact (Fig. 1 C).
Both transgenic soluble receptors in mouse sera were ca-
pable of binding recombinant APRIL in an ELISA assay,
demonstrating that they were produced in an active form.
While transgenic TACI:Fc also bound murine BAFF,
binding of soluble BCMA to murine BAFF was marginal
(Fig. 1 D). We can rule out that the weak binding observed
between BCMA and BAFF is due to a missfolding artifact,
because both proteins interacted well with another partner 
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(TACI for BAFF and APRIL for BCMA). The lack of a
BCMA:Fc/BAFF interaction stands in contrast with previ-
ous experiments in which the function of murine BAFF
was investigated using human BCMA:Fc (16). This appar-
ent discrepancy can be explained by the fact that murine
BCMA:Fc has a much lower affinity than human BCMA:
Fc for murine BAFF (Fig. 1 D).
Based on these binding studies, it was anticipated that in-
activation of BAFF may be considerably higher in TACI:Fc
than in BCMA:Fc transgenic mice. Indeed, while BCMA:
Fc transgenic mice displayed a normal B cell profile (Fig. 2
and data not shown), the analysis of TACI:Fc transgenic
mice revealed a pronounced B cell lymphopenia pheno-
type, which is summarized in Table I and Fig. 2. Pre-pro-B,
pro-B, pre-B, and transitional B cells were essentially
present in normal numbers and relative proportions in the
bone marrow, and only the population of mature recircu-
lating B cells was strongly reduced in TACI:Fc mice, sug-
gesting that the B cell defect occurred in the periphery (Fig.
2 A). The most immature B cell population of the spleen,
transitional T1 B cells, was normal or even slightly in-
creased in TACI:Fc mice (Fig. 2 B). This was in sharp con-
trast with the next maturation stage of transitional T2 B
cells, and with the downstream populations of marginal
zone and mature follicular B cells, which were either virtu-
ally absent or strongly reduced (Fig. 2 B). As a result, the
lymphocyte number in the spleen was decreased by 60%,
essentially due to the scarcity of the B cell compartment.
Interestingly, the absolute number of splenic T cells was
also reduced, although to a lesser extent. A reduction of
mature B cells was also observed in lymph nodes (Fig. 2 C)
 
and in peripheral blood lymphocytes (Fig. 2 D). In the lat-
ter, most remaining B cells were CD21-negative and lacked
the adhesion molecule L-selectin (CD62L), which is consis-
tent with a transitional B cell phenotype. In peritoneal exu-
date lymphocytes of TACI:Fc mice, there was a marked de-
crease of B2 B cells, but both subpopulations of B1 B cells
were still present (Fig. 2 E). As expected, populations of
thymic lymphocytes were normal in TACI:Fc mice (Fig. 2
F). Immunohistochemical analysis of spleen, lymph node,
and Peyer’s patches sections confirmed the atrophy of the
B cell compartment, but revealed that B and T cell seg-
regation was not altered (Fig. 3). Follicular dendritic
cells  (CD35
 
 
 
), dendritic cells (CD11c
 
 
 
), macrophages
(CD11b
 
 
 
), and germinal centers (PNA
 
 
 
, B220
 
 
 
) were dis-
tributed normally, except that cells and structures associated
with B cells were decreased accordingly (Fig. 3 and data not
shown). Consistent with the severe deficit of mature B cells
in TACI:Fc transgenic mice, serum levels of most Ig iso-
types were reduced compared with controls (Fig. 4). This
was particularly significant for the IgG1 and IgM isotypes.
A crucial role of BAFF in B cell homeostasis has been
firmly established by the generation of transgenic mice over-
expressing BAFF, which all suffer from B cell hyperplasia (7–
9). We have now generated a functional knockout of BAFF
by transgenic expression of a soluble form of the receptor
TACI. These mice have a severe defect in mature B cells,
pointing to a crucial role for BAFF in B cell development.
The phenotype of TACI:Fc mice is consistent with in vitro
data implying that BAFF is a survival factor for transitional
T2 B cells (18), and with the phenotype of BAFF transgenic
mice in which transitional T2 and marginal zone B cells are
Figure 1. Generation of TACI:Fc and BCMA:Fc transgenic mice. (A) Constructs
used for the generation of transgenic mouse. AAT, human  1-antitrypsin promoter; Fc,
human IgG1 linker, CH2, and CH3 domains; SP, Ig heavy chain signal peptide. Intron
and poly A addition sequences were from rabbit  -globin gene. (B) Genomic screen of
transgenic mice. The 252-bp band amplified by PCR is specific for human  1-anti-
trypsin promoter. (C) Western blot analysis of transgene expression. Serum (0.5  l) of
two independent lines of each TACI:Fc and BCMA:Fc transgenic mice and of nontransgenic controls were analyzed under nonreducing conditions and re-
vealed with horseradish peroxidase–coupled goat anti–human IgG antibody. Recombinant proteins (6 ng of BCMA:Fc and 12 ng of TACI:Fc) in normal se-
rum were loaded as standard. For transgenic mice, the serum concentration of the transgenic protein is indicated. Molecular weight standard are in kDa. (D)
Receptor-ligand interaction ELISA. Binding of recombinant murine BAFF (black circles), murine APRIL (white circles), or control murine TNF-  (white
diamonds) to immobilized recombinant or transgenic BCMA:Fc and TACI:Fc was monitored by ELISA. 
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the most enlarged populations (9, 18). In contrast, peritoneal
B1 B cells were only marginally affected in TACI:Fc mice,
suggesting that BAFF plays no major role in the generation
of this particular B cell lineage. However, it is noteworthy
that some BAFF transgenic mice have an enlarged B1 B cell
compartment, whereas other have not (7, 8).
The mechanisms driving maturation of B2 B cells in the
periphery are poorly understood. Signals through the B cell
receptor on immature B cells trigger cell death, yet muta-
tions affecting the B cell receptor or its signaling pathway
prevent B cell maturation (1, 19). Our work offers a possible
explanation for this paradox: signaling through the B cell re-
ceptor may be lethal for immature B cells unless the right
level of antiapoptotic signal is delivered at the same time,
possibly by BAFF. Because BAFF and the B cell receptor are
both critical for B cell maturation, B cell differentiation in
 
the periphery might result from a finely tuned balance be-
tween life and death signals. Recently, in vitro studies dem-
onstrated the specific survival effect of BAFF on transitional
T2 B cells, but not on transitional T1 B cells from which
they derive (18). Since BAFF has been shown to stimulate
NF-
 
 
 
B activation in resting and activated B cells and to
modulate the level of Bcl-2 family members, BAFF could
provide an NF-
 
 
 
B–dependent, antiapoptotic signal to T2 B
cells (20). This is consistent with the high expression of Bcl-2
monitored in B cells from BAFF transgenic mice (9),
which develop an autoimmune disease very similar to that
seen in mice with transgenic expression of Bcl-2 in the B
cell compartment or in mice deficient in the Bcl-2 antago-
nist, proapoptotic protein Bim (21, 22). Moreover, immu-
nodeficient (recombination activating gene [Rag]-1
 
 
 
/
 
 
 
)
mice reconstituted with hematopoietic precursor cells from
Figure 2. FACS® analysis of lymphoid organs of TACI:Fc and BCMA:Fc transgenic mice. The indicated percentages refer to gated lymphocytes. (A)
Bone marrow. Lymphocytes expressing the B cell lineage marker B220 were separated according to CD43 expression and further analyzed with CD24
and BP-1 (for CD43  cells) and IgM and IgD (for CD43  cells). Populations A (pre-pro-B), B (pro-B), C (pro-B/PreB), D (pre-B), E (transitional B),
and F (recirculating mature B) are labeled according to Hardy’s nomenclature (reference 29). (B) Spleen. Analysis of splenic B (B220 ) and T (CD3 ) cell
populations, and four color FACS® analysis of splenic B cell populations based on B220, CD23, CD21, and surface IgM expression (references 2 and 18).
FO, follicular B cells; MZ, marginal zone B cells; T1, transitional T1 B cells; T2, transitional T2 B cells. (C) Inguinal lymph nodes. Analysis of B cell
populations based on B220 and IgD. (D) Peripheral blood lymphocytes. Analysis of B cell populations based on the expression of B220, CD62L (L-selec-
tin), and CD21. (E) Peritoneal exudate lymphocytes. Peritoneal B lymphocytes are classified into B1 and B2 cells based on the expression level of CD23,
and further analyzed for CD5 and IgM expression. B1a, CD5  B1 B cells; B1b, CD5  B1 B cells. (F) Thymus. Thymocytes are analyzed based on the
expression of CD4, CD8, TCR-  , and TCR-  . ISP, immature CD8 single positive precursor T cells; NKT, NK T cells. 
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Table I.
 
Lymphocytes Counts in TACI:FC Transgenic Mice and Control Littermates
 
Cell number (
 
 
 
10
 
6
 
)
Controls TACI:Fc
 
P
 
 value Controls TACI:Fc
 
P
 
 value
Spleen
All cells 63.5 
 
 
 
 7.1 25.0 
 
  
 
2.9
 
**
 
100 100
T cells 12.3 
 
 
 
 1.2 9.3 
 
 
 
 1.4 19.5 
 
  
 
2.1 36.9
 
   
 
1.8
 
**
 
CD4
 
 
 
9.1 
 
 
 
 0.8 6.2 
 
 
 
 0.6
 
*
 
14.4 
 
 
 
 1.3 25.0 
 
 
 
 1.1
 
**
 
CD8
 
 
 
3.3 
 
  
 
0.3 2.9 
 
  
 
0.9 5.3 
 
 
 
 0.7 11.5 
 
 
 
 2.1
 
*
 
B cells 44.8 
 
 
 
 5.0 9.3 
 
 
 
 3.7
 
**
 
70.5
 
  
 
 2.2 37.8
 
   
 
5.1
 
**
 
T1 1.9 
 
 
 
 0.3 3.3 
 
 
 
 0.4 3.0 
 
  
 
0.3 13.5 
 
 
 
 2.6
T2 2.6 
 
  0.1 0.045   0.022 *** 4.2   0.3 0.19   0.09 ***
MZ 1.4   0.3 0.050   0.014 ** 2.3   0.6 0.21   0.08 **
FO 36.1   5.6 2.0   0.3 ** 56.6   2.6 8.3   1.7 **
Thymus
All cells 122.3   12.0 133.7   14.4 100 100
CD4 /CD8  107.2  10.5 113.5   12.9 87.6   0.3 85.0   3.4
CD4  0.84   0.05 1.17   0.33 6.9   0.2 8.7   2.2
CD8  0.17   0.04 0.24   0.08 1.4   0.4 1.8   0.6
Immat. CD8  0.049   0.023 0.47   0.005 0.41   0.19 0.36   0.08
   0.016   0.003 0.021   0.004 0.13   0.01 0.16   0.02
 
Bone marrow
All cells 44.8   3.1 32.1   3.0 * 100 100
Pro-B/pre-B 4.6   0.4 4.2   1.4 10.2   0.3 13.1   3.3 *
Pre-B/Imm. B 13.6   0.5 8.8   0.8 * 30.6   1.5 27.5   1.8
Recirculating B 3.0   0.2 0.53   0.09 *** 6.6   0.5 1.6   0.1 ***
Lymph node
CD4  ND ND 36.1   2.4 48.6   1.0 *
CD8  ND ND 26.4   2.3 33.5   1.8 *
B cells ND ND 35.5   2.0 5.6   2.2 **
PBLs
All cells 8.2   1.1 5.5   0.8 ** 100 100
2.5   0.3 2.9   0.5 30.5   1.8 51.7   3.8 **
1.5   0.2 1.8   0.3 * 18.6   1.3 31.8   2.2 **
0.98   0.15 1.1   0.2 12.0   0.6 19.2   1.6 **
4.8   0.7 1.4   0.1 ** 58.1   2.9 26.5   5.6 **
0.28   0.08 0.47   0.07 ** 3.3   0.7 8.7   1.2 **
3.4   0.6 0.35   0.04 ** 41.0   2.6 6.5   0.5 ***
PEL’s Ratio
B2/B1 ratio 0.48   0.16 0.056   0.039 **
Cell numbers are in million per organ. For bone marrow, numbers are for one tibia and one femur. For PBLs, numbers are for 1 ml of blood. Three
mice (9-wk-old females) were analyzed in each group.
P values: *0.2   P   0.05; **0.05   P   0.01; ***P   0.01.
Population definition: Spleen: T1 (B220 , CD23 , CD21 , IgM ); T2 (B220 , CD23 , CD21  , IgM  ); MZ (B220 , CD23 , CD21  ,
IgM  ); FO (B220 , CD23 , CD21 , IgM ). Thymus: Immature CD4  (CD4 , TCR-   );    (CD4 , CD8 , TCR-   ). Bone marrow: pro-
B/pre-B (B220 , CD43 ); pre-B/immature B (B220 , CD43 , IgD  or low); recirculating B (B220 , CD43 , IgD ). PBLs: immature B (B220 ,
CD23 ); mature B (B220 , CD23 ). PELs: B2 (B220 , CD23 , CD5 ); B1 (220 , IgM , CD23 , CD5  or  ).1696 B Cell Maturation Requires BAFF
c-Rel /  RelA /  double deficient mice display a block in
B cell maturation remarkably similar, if not identical, to that
observed in the TACI:Fc transgenic mice. This maturation
arrest correlates with defects in the upregulation of Bcl-2
and A1 antiapoptotic proteins and is rescued to a large extent
by enforced expression of Bcl-2 (23). Therefore, a likely sce-
nario in the TACI:Fc transgenic mouse involves sequestra-
tion of BAFF by the transgenic decoy receptor, lack of
BAFF-mediated NF- B signals resulting in deficient expres-
sion of antiapoptotic proteins such as Bcl-2. As a result,
newly formed T2 B cells express levels of antiapoptotic pro-
teins that are below the threshold required for survival and
differentiation into mature and/or marginal zone B cells.
In view of the fact that BAFF and APRIL share BCMA
and TACI as receptors, an essential role of APRIL in B cell
biology has been proposed (10, 11). However, comparison
of TACI:Fc and BCMA:Fc mice suggest that APRIL is not
essential for B cell development because BCMA:Fc mice
have no B cell phenotype. If, for some unknown reasons,
endogenous APRIL is not inhibited by the two soluble re-
ceptors, the phenotype of TACI:Fc mice would still imply
that APRIL cannot substitute for BAFF.
Inactivation of the receptor through which BAFF signals
in transitional B cells is expected to result in a severe B cell
deficiency. BCMA is unlikely to mediate these effects, first
because of its low affinity for BAFF (Fig. 1), and second
because the B cell compartment of BCMA-deficient mice
is not affected (12). Thus, TACI, which binds well to
BAFF, is likely to be responsible for the BAFF-mediated
signals. Yet, the phenotype of TACI-deficient mice (13,
14) drastically differs from that of the functional BAFF
knockout. In fact, rather than having less B cells, these
mice display a moderate B cell hyperplasia. The recent
cloning of a novel BAFF-specific receptor, which in con-
trast to TACI and BCMA does not interact with APRIL,
provides an additional candidate for mediating BAFF ef-
fects on B cell maturation (24). Indeed, disruption of the
BAFF-R locus in A/WySnJ mice is associated with a B cell
phenotype closely related to that of the TACI:Fc transgenic
mice or to the recently described BAFF /  mice, strongly
suggesting that BAFF mediates its B cell maturation signal
through BAFF-R (24–27).
The fact that TACI-deficient mice have an increased
number of B cells raises the hypothesis that TACI may fulfill
an inhibitory or regulatory role. In this context, it is of inter-
est that the two sites involved in proteolytic processing of
TACI:Fc in the transgenic mice are conserved between hu-
man and mouse sequences. Therefore, it is not excluded that
shedding of membrane-bound TACI, similar to TNF recep-
tors (28), may have a physiological regulatory function.
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Figure 3. Immunohistochemistry of fro-
zen spleen, lymph node, and Peyer’s patches
sections. Spleen. Serial sections were double
stained with B cells (anti-B220, brown), T
cells (anti-CD3 , purple), follicular den-
dritic cells (anti-CD35/Cr1, purple), mac-
rophages (CD11b, brown) and dendritic
cells (CD11c, purple) markers, as indicated.
Inguinal lymph nodes and Peyer’s patches
were doubly stained for B and T cells.
Peyer’s patches were present in normal
number in TACI:Fc mice, but had a smaller
size. Bars   100  m.
Figure 4. Reduced Ig levels in TACI:Fc mice. Ig levels were deter-
mined in normal serum of TACI:Fc transgenic mice and matched control
littermates. P values: *0.2   P   0.05; **0.05   P   0.01; ***P   0.01.1697 Schneider et al. Brief Definitive Report
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